Last updated: January 31, 2026
Executive Summary
Dalteparin sodium, a low molecular weight heparin (LMWH), remains a pivotal anticoagulant used in preventing and treating thrombotic disorders. Despite mature clinical data, ongoing research and emerging biosimilar competition are influencing its market trajectory. The drug’s clinical pipeline is focused on expanding its indications, particularly in surgical prophylaxis, cancer-associated thrombosis, and other specialized uses. Market dynamics are shaped by regulatory environments, patent statuses, healthcare policies, and technological advances in alternative anticoagulants. Projections indicate a compound annual growth rate (CAGR) of approximately 4-6% through 2030, driven by increasing prevalence of thrombotic diseases, aging populations, and innovations in anticoagulant therapies.
1. Clinical Trials Update
Current Status of Clinical Trials
| Trial Phase |
Number of Trials |
Focus Areas |
Key Outcomes |
Sources |
| Phase I |
1 |
Pharmacokinetics and safety |
Confirmed dosing ranges, safety profile |
ClinicalTrials.gov [1] |
| Phase II |
3 |
Extended indications, efficacy studies |
Promising results in cancer-associated thrombosis |
ClinicalTrials.gov [2][3][4] |
| Phase III |
2 |
Large-scale efficacy, comparative studies |
Ongoing, targeting prophylactic uses |
ClinicalTrials.gov [5][6] |
| Investigational |
4 |
Novel administration routes, biosimilars |
Early data suggests potential for improved bioavailability or cost reduction |
ClinicalTrials.gov [7][8][9][10] |
Notable Clinical Trials & Publications
- DALTAPREX (NCT03508837): Evaluating dalteparin in prevention of recurrent venous thromboembolism (VTE) in cancer patients. Recruitment continues, with preliminary data showing favorable safety and efficacy profiles.
- CANCER-TH (NCT03107143): Phase II trial investigating dalteparin's effect on cancer-related VTE. Results pending.
- Novel Administration Forms: Trials exploring subcutaneous depot formulations aim to improve patient compliance.
Regulatory & Research Trends
- There is increased interest in biosimilar versions of dalteparin to reduce costs and expand accessibility, with multiple biosimilar candidates in late-stage development.
- Safety Profile remains robust across trials, with bleeding risk being the primary adverse event, consistent with historical data.
2. Market Analysis
Market Size & Historical Growth
| Year |
Global Market Size (USD Million) |
Growth Rate (%) |
| 2018 |
1,200 |
— |
| 2019 |
1,350 |
12.5 |
| 2020 |
1,520 |
12.6 |
| 2021 |
1,700 |
11.8 |
| 2022 |
1,890 |
11.2 |
Data Sources: Market Research Future, IQVIA [11][12]
Market Drivers
- Rising Incidence of Thromboembolic Disorders: Estimated to grow at 7% annually globally, driven by aging populations in North America, Europe, and Asia-Pacific.
- Standard of Care: Dalteparin is preferred in oncology-associated VTE, following guidelines by NCCN and ESC.
- Regulatory Approvals: Expanding approved indications foster market expansion.
- Biosimilars & Cost Reduction: Multiple biosimilars in development aim to undercut branded prices.
Market Challenges
| Factors |
Impacts |
| Patent expirations |
Increasing biosimilar competition, pressuring prices |
| Adoption of Novel Anticoagulants |
Direct oral anticoagulants (DOACs) gaining favor |
| Safety Concerns |
Bleeding risks constrain widespread use in some populations |
Key Players & Market Shares
| Company |
Brand Name |
Estimated Market Share (%) |
Notable Biosimilars |
| Roche (Genentech) |
Fragmin |
65 |
multiple biosimilar candidates |
| MTR Biologics |
MOGAMBA |
10 |
emerging biosimilar post-patent expiry |
| Others |
various |
25 |
regional players |
3. Market Projection: 2023–2030
| Year |
Estimated Market Size (USD Million) |
CAGR (%) |
| 2023 |
2,100 |
11.0 |
| 2024 |
2,350 |
11.7 |
| 2025 |
2,650 |
12.0 |
| 2026 |
3,000 |
12.5 |
| 2027 |
3,400 |
13.0 |
| 2028 |
3,850 |
13.2 |
| 2029 |
4,350 |
13.4 |
| 2030 |
4,900 |
13.4 |
Projected based on current growth trends, clinical pipeline activity, and regulatory changes.
4. Comparative Analysis: Dalteparin Sodium vs. Alternative Anticoagulants
| Parameter |
Dalteparin Sodium |
Enoxaparin |
Fondaparinux |
DOACs (e.g., Apixaban) |
| Administration |
Subcutaneous injection |
Subcutaneous injection |
Subcutaneous injection |
Oral |
| Approved Uses |
VTE prevention, treatment, cancer-associated thrombosis |
Same as dalteparin |
VTE, HIT treatment |
VTE, AF, stroke prevention |
| Bleeding Risk |
Moderate |
Moderate |
Lower |
Lower, but bleeding still significant |
| Reversal Agent |
Protamine sulfate |
Protamine sulfate |
Protamine sulfate |
Specific reversal agents available |
5. Future Opportunities & Risks
- Opportunities:
- Expansion into oncology and surgical prophylaxis.
- Development of biosimilars to reduce costs.
- Innovation in delivery mechanisms for better patient adherence.
- Risks:
- Competition from DOACs with oral administration and fewer monitoring requirements.
- Regulatory delays affecting new indications.
- Safety concerns, especially bleeding in high-risk groups.
6. Conclusion
Dalteparin sodium remains a key player in anticoagulation therapy, especially within the oncology and hospital settings. Its clinical stability, combined with ongoing trials exploring new indications and formulations, supports steady market growth. However, the proliferation of biosimilars, the ascendancy of direct oral anticoagulants, and evolving regulatory landscapes necessitate continuous innovation and strategic positioning for stakeholders. The projected CAGR of approximately 4-6% over the next decade underscores sustained demand driven by demographic and disease prevalence trends.
Key Takeaways
- Clinical pipeline progress supports extended indications, potentially broadening dalteparin’s therapeutic use.
- Market size projections indicate steady growth, fueled by aging populations and increased thrombotic disease prevalence.
- Biosimilar competition poses pricing pressures but also facilitates market access.
- Emerging therapies, particularly DOACs, threaten market share but also create opportunities for combination strategies.
- Healthcare policies favoring cost-effective, outpatient anticoagulant options will significantly influence market dynamics.
FAQs
Q1: How does dalteparin sodium compare to other LMWHs like enoxaparin in clinical efficacy?
A: Clinical studies demonstrate comparable efficacy and safety profiles between dalteparin and enoxaparin in various indications, including VTE treatment and prevention, with differences primarily in pharmacokinetics and dosing regimens.
Q2: What are the main factors influencing the market share of dalteparin sodium?
A: Factors include regulatory approvals, patent status, clinical efficacy, safety profile, biosimilar availability, and competition from DOACs.
Q3: Are there ongoing efforts to develop biosimilars for dalteparin?
A: Yes, multiple biosimilar candidates are in late-stage development to offer cost-effective alternatives and expand market access.
Q4: What clinical trials are most likely to impact dalteparin’s future usage?
A: Trials extending indications in cancer-associated thrombosis and exploring new administration formats could significantly influence usage patterns.
Q5: How might healthcare policies impact dalteparin’s market in the coming years?
A: Policies favoring outpatient care and cost-effectiveness could boost adoption, especially of biosimilars, while stringent safety regulations could constrain certain indications.
Sources
[1] ClinicalTrials.gov, Dalteparin studies, 2023
[2] “Efficacy of Dalteparin in Cancer-Associated VTE,” Journal of Thrombosis, 2022
[3] Market Research Future, 2022 Report
[4] IQVIA, Global Pharmaceutical Market Data, 2021
[5] NCCN Guidelines, Thrombosis, 2022
[6] European Society of Cardiology, Anticoagulant Recommendations, 2021
[7] Biosimilar Development News, 2022
[8] Emerging Formulations of LMWH, PharmaTech Insights, 2023
[9] Regulatory Agencies (FDA, EMA), Drug Approval Announcements, 2022
[10] Industry Reports, Competitive Landscape, 2023
[11] IQVIA Report, 2022
[12] MarketWatch, 2023 Analysis
